Generium to raise its annual output of anti-COVID-19 vaccine up to 200-300 million doses
22.03.2021
Finanz.ru
Generium plans to bring its anti-COVID-19 vaccine production up to 200-300 million doses annually, announced Pharmstandard Chairman of the Board Viktor Kharitonin during the conference with President of Russia Vladimir Putin.
'Today we are making this call from our new manufacturing building which will significantly increase the vaccine output, up to 200–300 million doses per year', said Viktor Kharitonin.
He pointed out that the company had started working on the Sputnik V vaccine with the Gamaleya Research Centre in August 2020. 'We promptly completed the laboratory technology transfer, scaled and mastered the technology at our site. The first batches of vaccines we manufactured hit healthcare institutions across Russia as early as the first days of November. As of today, our three manufacturing sites have produced over 17 million doses of the vaccine', noticed Mr Kharitonin.
According to Mr Kharitonin, Generium and Pharmstandard have supplied nearly 90% of Russia's vaccination programme requirement. 'Breaking our previous output records, 6 million doses were manufactured within three weeks of March alone', he stressed. Thanks to the cooperation with the Direct Investment Fund, Generium has launched the vaccine supply to foreign markets, Viktor Kharitonin added. 'We have transferred the manufacturing technology to Kazakhstan, and we're working with other countries, like India and Italy, for instance', concluded V. Kharitonin.
Source
Link: https://www.finanz.ru/novosti/aktsii/generium-planiruet-uvelichit-proizvodstvo-vakciny-covid-19-do-200-300-mln-doz-v-god-1030232926
|
Пресса о нас
Generium to raise its annual output of anti-COVID-19 vaccine up to 200-300 million doses
Finanz.ru, 22.03.2020
Generium plans to bring its anti-COVID-19 vaccine production up to 200-300 million doses annually, announced Pharmstandard Chairman of the Board Viktor Kharitonin during the conference with President of Russia Vladimir Putin.
'Today we are making this call from our new manufacturing building which will significantly increase the vaccine output, up to 200–300 million doses per year', said Viktor Kharitonin.
He pointed out that the company had started working on the Sputnik V vaccine with the Gamaleya Research Centre in August 2020. 'We promptly completed the laboratory technology transfer, scaled and mastered the technology at our site. The first batches of vaccines we manufactured hit healthcare institutions across Russia as early as the first days of November. As of today, our three manufacturing sites have produced over 17 million doses of the vaccine', noticed Mr Kharitonin.
According to Mr Kharitonin, Generium and Pharmstandard have supplied nearly 90% of Russia's vaccination programme requirement. 'Breaking our previous output records, 6 million doses were manufactured within three weeks of March alone', he stressed. Thanks to the cooperation with the Direct Investment Fund, Generium has launched the vaccine supply to foreign markets, Viktor Kharitonin added. 'We have transferred the manufacturing technology to Kazakhstan, and we're working with other countries, like India and Italy, for instance', concluded V. Kharitonin.
Source Link: https://www.finanz.ru/novosti/aktsii/generium-planiruet-uvelichit-proizvodstvo-vakciny-covid-19-do-200-300-mln-doz-v-god-1030232926
|
